BioMarin Pharmaceutical Inc BMRN

Morningstar Rating
$55.95 +0.41 (0.74%)
View Full Chart

Company Report

Price vs Fair Value

BMRN is trading at a 330% premium.
Price
$55.95
Fair Value
$93.00
Uncertainty
Ykpy
1-Star Price
$648.30
5-Star Price
$39.00
Economic Moat
Pnjstw
Capital Allocation
Ndtbxpmn

Bulls Say, Bears Say

Bulls

BioMarin's approved drugs have been granted orphan-drug status in the US and the EU, providing them with at least seven and 10 years of market exclusivity, respectively.

Bears

Diagnosis of very rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.

News

Articles & Videos

Trading Information

Previous Close Price
$55.54
Day Range
$55.4856.26
52-Week Range
$49.2666.28
Bid/Ask
$53.72 / $57.78
Shares Outstanding
193.28M
Market Cap
$10.81B
Volume/Avg
1M / 2M

Key Statistics

Price/Earnings (Normalized)
18.58
Price/Sales
3.39
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
3,221

Competitors

Valuation

Metric
BMRN
SNY
PFE
Price/Earnings (Normalized)
18.5810.478.55
Price/Book Value
1.731.271.66
Price/Sales
3.391.962.36
Price/Cash Flow
10.578.978.74
Price/Earnings
BMRN
SNY
PFE

Financial Strength

Metric
BMRN
SNY
PFE
Quick Ratio
3.940.200.85
Current Ratio
5.811.011.25
Interest Coverage
14.3611.823.73
Quick Ratio
BMRN
SNY
PFE

Profitability

Metric
BMRN
SNY
PFE
Return on Assets (Normalized)
7.67%7.49%8.40%
Return on Equity (Normalized)
9.74%13.70%19.47%
Return on Invested Capital (Normalized)
8.09%10.47%12.80%
Return on Assets
BMRN
SNY
PFE

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
DrsffhfrGdltxz$113B
Regeneron Pharmaceuticals Inc
REGN
DncpvybQvsxfg$64B
argenx SE ADR
ARGX
TgszrqfmnLxsp$56B
Alnylam Pharmaceuticals Inc
ALNY
NrsbggsYrydrn$38B
Royalty Pharma PLC Class A
RPRX
HwmrhwprbKpljzzl$24B
BioNTech SE ADR
BNTX
GtrnhlgpqFnj$23B
Incyte Corp
INCY
GsvwmgtBryw$22B
Moderna Inc
MRNA
ZfcylgfwtRkt$20B
Jazz Pharmaceuticals PLC
JAZZ
CdvxqbmqZwm$14B
BridgeBio Pharma Inc
BBIO
RwxchpzyRlsfz$13B

Sponsor Center